Titan portfolio company stories: myTomorrows
Taking a revolutionary approach to fighting diseases
myTomorrows is set to revolutionise an industry valued at an estimated $500 billion worldwide, by giving patients early access to potentially life-saving treatments.
Improving access to drugs in development
Developing drugs to fight diseases is a slow and complex process. MyTomorrows assists with regulatory hurdles to streamline patients getting pre-approval access, and identifies emerging treatments using the latest technology.
This company example is for illustrative purposes only. It should not be considered as an investment recommendation. Any personal opinions mentioned may change and should not be seen as advice or a recommendation.
Octopus Titan VCT risks
Please remember that the value of an investment in Octopus Titan VCT, and any income from it, can fall as well as rise. Investors may not get back the full amount they invest.
Tax treatment depends on individual circumstances and may change in the future. Tax reliefs depend on the VCT maintaining its qualifying status.
The shares of the smaller companies we invest in could fall or rise in value more than shares listed on the main market of the London Stock Exchange. They may also be harder to sell.
Investors should only subscribe for shares on the basis of information contained in the prospectus and Key
Information Document (KID), available on the Octopus Titan VCT product page.
More from Titan VCT
Reimagining women’s technology.
We’re here to support you
If you’ve got a question about any of our products or services, please get in touch.
Contact our team
Got a question?
Call us at 0800 316 2067